The anthrax treatment market — antibiotics, monoclonal antibody antitoxins, and vaccines used to treat and prevent Bacillus anthracis infection, spanning cutaneous, gastrointestinal, and the far more lethal inhalational form of the disease — remains one of the more unusual pharmaceutical categories in that it is driven almost entirely by government biodefense stockpiling rather than...